We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Catheters in Dialysis Linked to High Risk of Infection

By HospiMedica International staff writers
Posted on 03 Mar 2013
A new study shows that dialysis patients using catheters for blood access have the highest risks for death, infections, and cardiovascular (CV) events.

Researchers at the University of Calgary (Canada), the University of Otago (Christchurch, New Zealand), and other institutions conducted a systematic review of cohort studies to evaluate the associations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and risk for death, infection, and major CV events. The researchers searched MEDLINE, EMBASE, and other article reference lists and extracted data describing study design, participants, vascular access type, clinical outcomes, and risk for bias. In all, 62 cohort studies comprising 586,337 participants met the inclusion criteria.

The results showed that when compared with patients with an arteriovenous fistula, those using catheters had a 38% higher risk of experiencing a major heart-related event, a 53% higher risk of dying, and more than twice the risk of developing fatal infections. Patients with arteriovenous grafts had an 18% increased risk of dying and a 36% increased risk of developing fatal infections compared to those with an arteriovenous fistula, but they did not have an increased risk of experiencing a major heart-related event. The study was published early online on February 21, 2013, in the Journal of the American Society of Nephrology (JASN).

“Our findings are reflected in current clinical practice guidelines, which promote fistulas as the preferred form of bloodstream access in hemodialysis patients,” said lead author Pietro Ravani, MD, of the University of Calgary, and colleagues. “Better quality data are needed, but not from studies with the same design as those already available. In fact, our cumulative meta-analysis shows that this information was already available 10 years ago.”

An arteriovenous fistula is currently the most recommended access for kidney disease patients who must undergo dialysis, created by connecting a patient's vein and artery to form a long-lasting site through which blood can be removed and returned. Alternatively, in patients who are unsuitable for a fistula, an arteriovenous graft—a plastic conduit between an artery and a vein—may be used. Many patients, however, prefer a catheter, for reasons that include inadequate preparation for dialysis, avoidance of surgery, or fear of needles (since the connection to the dialysis machine via a catheter does not require needles).

Related Links:

University of Calgary
University of Otago



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Ultrasound Needle Guidance System
SonoSite L25
New
Knee Arthroscopy Holder
Reison 10-353 XL

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more